TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02148354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smiling is Fun
Description: Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else...?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smiling is Fun
Description: Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else...?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress.
Study: NCT02025218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib standard dose
Study: NCT02148354

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smiling is Fun
Description: Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else...?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress.
Study: NCT02813382

Intervention type: DRUG
Intervention: Bupivacaine
Description: Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).

Intervention type: DRUG
Intervention: Prilocaine
Description: Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).

Intervention type: DRUG
Intervention: Chloroprocaine
Description: Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
Study: NCT01123187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: islet transplantation
Description: Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
Study: NCT01652586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine-remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam-remifentanil
Study: NCT04290494

Intervention type: DRUG
Intervention: IV rtPA (intravenous recombinant plasminogen activator)
Description: intravenous injection

Intervention type: DRUG
Intervention: IV rtPA (intravenous recombinant plasminogen activator)
Description: intravenous injection

Intervention type: DRUG
Intervention: IV rtPA (intravenous recombinant plasminogen activator)
Description: intravenous injection
Study: NCT01362296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: IV once every 3 weeks
Study: NCT01763255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell intrathecal injection
Description: Intrathecal injection of Bone marrow derived CD133 cells
Study: NCT01397266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: ACTIVE rTMS delivered to the left dorsolateral prefrontal cortex

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TMS
Description: PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
Study: NCT02033317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: 15 grams/day (5 grams 3 times daily) administered orally
Study: NCT03476681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEO-201 in combination with pembrolizumab
Description: NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.
Study: NCT01530906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial Magnetic Stimulation (rTMS)
Description: 10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive transcranial Magnetic Stimulation SHAM
Description: Sham treatment will be performed with a placebo coil. The same coil as coil used for rTMS, but it does not deliver magnetic field.
Study: NCT03689894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Subjects will receive oral (PO) Ibrutinib 140 mg once daily with Rituximab 375 mg per meter squared IV weekly x4 (with pre-medications and infusion procedure as per standard protocol) Rituximab Pre-medications:Acetaminophen 650 mg PO; Diphenhydramine 25 mg PO/IV; Dexamethasone 20 mg IV.~If no adverse events \>Grade 3+ are noted after 1 week, the Ibrutinib dose schedule will be increased to 280 mg daily. If no adverse events \>Gr3+ are noted after an additional 1 week, the Ibrutinib dose will be increased to 420 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Subject will receive an intravenous infusion of 375mg per meter squared weekly for 4 weeks, which may be repeated 8 weeks after initial therapy if only a suboptimal response is achieved.
Study: NCT00975637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70 mg SC
Description: 70 mg SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 210 mg SC
Description: 210 mg SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg SC
Description: 140 mg SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 280 mg SC
Description: 280 mg SC
Study: NCT00310141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Description: 6 weeks of computer delivered treatment for quitting smoking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation intervention
Description: 6 weeks of computer delivered treatment for quitting smoking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Description: In-person counseling (5 sessions)
Study: NCT02992457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 1000-1200 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 1000-1200 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated-interferon alfa-2a
Description: Pegylated interferon alfa-2a once weekly for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simeprevir
Description: Olysio once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Dakla once daily for three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritaprevir, paritaprevir, ombetasvir
Description: Querevo for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir and Ledipasvir
Description: Once daily for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvage therapy
Description: three months in repeated treatment failure
Study: NCT00310141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling intervention
Description: In-person counseling (5 sessions)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling intervention
Description: In-person counseling (5 sessions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 6-week supply of the nicotine patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: 6-week supply of the nicotine patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: 6-week supply of the nicotine patch
Study: NCT04269863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: control - 81mg. treatment - 81-325mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: control - 81mg. treatment - 81-325mg.
Study: NCT01764932

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fluoroscopic imaging
Description: Contrast media (5 mL) will be injected through the catheter and fluoroscopic images will be obtained and saved in the lateral and antero-posterior projections.
Study: NCT04731597

Intervention type: DRUG
Intervention: drug interaction
Description: when two drugs are taken together
Study: NCT00975637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo SC
Study: NCT01528215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed EV
Description: OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OsseoSpeed TX
Description: OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
Study: NCT01833546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evofosfamide
Description: Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m\^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evofosfamide
Description: Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m\^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evofosfamide
Description: Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m\^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evofosfamide
Description: Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m\^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
Study: NCT02171572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate high
Study: NCT02443116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02613286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrafascial Hysterectomy
Description: Hysterectomy plus Pelvic Lymph-Node Dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified radical hysterectomy
Description: Hysterectomy plus Pelvic Lymph-Node Dissection
Study: NCT03141788

Intervention type: DEVICE
Group type: OTHER
Intervention: Clear Aligner
Description: Clear Aligner used to straighten teeth to desired outcome
Study: NCT00840047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methionine
Description: Intravenous injection
Study: NCT03523702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PembroRT
Description: Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year.~Patients whose tumors are found to have low (\< 50%) PD-L1 will be treated with a standard-o-care regimen and not be a part of this clinical trial.
Study: NCT04117893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-articular injection of corticosteroid and hyaluronic acid
Description: Participants will receive a 3.5 ml intra-articular injection of 30mg of hyaluronic acid plus 10mg of triamcinolone acetonide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular injection of corticosteroid and hyaluronic acid
Description: Participants will receive a 3.5 ml intra-articular injection of 30mg of hyaluronic acid plus 10mg of triamcinolone acetonide.
Study: NCT00557245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate (TDF)
Description: TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
Description: FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo TDF \& Placebo FTC/TDF, 1 tablet each daily.
Study: NCT04731493

Intervention type: OTHER
Intervention: Therapeutic Education Program
Description: * needs assessment~* educational group workshop~* specialized workshops by age group: child / adolescent / transition / adult / entourage / separated parents and in parallel~* socio-administrative workshop~* individual summary (accompanied or not by his entourage / family)~* satisfaction questionnaire
Study: NCT03476031

Intervention type: DIAGNOSTIC_TEST
Intervention: renal biopsy
Description: needle biopsy will be taken from the kidney tissue then, diagnosed
Study: NCT01571817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isolated Human Pancreatic Islets
Study: NCT04015531

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: 50 Gy / 25 fractions / 5-6 weeks / Sequential boost of 10 Gy in 5 fractions, in case of conservative surgery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: 40 Gy / 15 fractions / 3 weeks / Concomitant boost with total dose of 48 Gy in 15 fractions, in case of conservative surgery.
Study: NCT00378027

Intervention type: DRUG
Intervention: Fondaparinux
Description: Administer Fondaparinux Risk Stratify
Study: NCT03011879

Intervention type: OTHER
Intervention: clinical pathway

Intervention type: OTHER
Intervention: clinical pathway

Intervention type: OTHER
Intervention: clinical pathway
Study: NCT03195452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)
Description: All virologically suppressed
Study: NCT02277951

Intervention type: DEVICE
Intervention: The Bonfils Intubation Fibrescope
Description: Effectiveness and time to successful intubation will be measured.

Intervention type: DEVICE
Intervention: The Video Rigid Flexing Laryngoscope
Description: Effectiveness and time to successful intubation will be measured.

Intervention type: DEVICE
Intervention: The C-MAC® S Video Laryngoscope
Description: Effectiveness and time to successful intubation will be measured.

Intervention type: DEVICE
Intervention: The Macintosh Laryngoscope
Description: Effectiveness and time to successful intubation will be measured.
Study: NCT03310619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: Gene modified autologous T cells
Study: NCT02993029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99Tc-MDP
Description: 99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib capsule 200mg qd by mouth.
Study: NCT01922674

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard open tension-free inguinal hernia repair with mesh
Study: NCT03211546

Intervention type: PROCEDURE
Intervention: Conservative (non-surgical) treatment
Description: Spica cast Traction Traction and spica cast

Intervention type: PROCEDURE
Intervention: Surgical treatment
Description: Elastic Stable Intramedullary Nailing (ESIN) Conventional locking intramedullary nail Plating External fixation
Study: NCT03340116

Intervention type: PROCEDURE
Intervention: Burn surgery
Description: Burn surgery including wound debridement, skin grafting

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
Description: Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
Description: Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
Study: NCT02632643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor education with a view to obtaining an optimal FWS further to the relaxation of the masticatory, lingual and labial system. Learning of mandibular micro-movements in 5 directions.
Study: NCT03236831

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Recommendations
Description: The investigators will provide clinical recommendations to the subject's primary care provider. These will be in regards to the following:~1. Avoidance of potentially nephrotoxic medications.~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Minimizing IV contrast exposure when appropriate~5. Treating severe anemia~6. Optimization of hemodynamics (Mean arterial BP\>65mmHg)
Study: NCT02394067

Intervention type: OTHER
Intervention: Radiological Imaging
Description: magnetic resonance imaging and magnetic resonance venography scans
Study: NCT02380235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: 0.20mg/kg/w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: 0.20mg/kg/w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: 0.12mg/kg/w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: 0.12mg/kg/w
Study: NCT02120248

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-based breastfeeding peer counseling

Intervention type: OTHER
Group type: OTHER
Intervention: Telephone-based breastfeeding peer counseling
Study: NCT01515215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specific brain regions. (MagPro X100)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specific brain regions. (MagPro X100)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specific brain regions. (MagPro X100)
Study: NCT03924284

Intervention type: DIAGNOSTIC_TEST
Intervention: PB2 gene RT-PCR; NS gene RT-PCR
Description: PB2 gene RT-PCR: RT-PCR targeting the PB2 gene of influenza A virus NS gene RT-PCR: RT-PCR targeting NS gene of influenza A virus

Intervention type: DIAGNOSTIC_TEST
Intervention: PB2 gene RT-PCR; NS gene RT-PCR
Description: PB2 gene RT-PCR: RT-PCR targeting the PB2 gene of influenza A virus NS gene RT-PCR: RT-PCR targeting NS gene of influenza A virus
Study: NCT02795793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-operative management group (NOM)
Description: With intravenous Piperacillin with Tazobactam (Tazocin)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy group (Operative management, OM)